Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.47 |
| ▸ | TOP2A | P11388 | 2/20 | 0.41 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 5/20 | 0.40 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14416026 | 0.79 | ATM (0.47) | ATMELANECCR1CYP3A4 | |
| SCHEMBL5118303 | 0.77 | ALDH1A1 (0.43) | POLBCYP3A4 | |
| SCHEMBL13963460 | 0.76 | SMN1; SMN2 (0.47) | ATMELANECCR1CYP3A4 | |
| SCHEMBL13973864 | 0.74 | ROCK2 (0.48) | ATMELANECCR1CYP3A4 | |
| SCHEMBL5648475 | 0.73 | KIF11 (0.50) | CYP3A4 | |
| SCHEMBL5646819 | 0.73 | KIF11 (0.50) | CYP3A4 | |
| SCHEMBL5649327 | 0.73 | KIF11 (0.50) | CYP3A4 | |
| SCHEMBL7412044 | 0.71 | MAPT (0.49) | AAK1ATMELANE | |
| SCHEMBL5111971 | 0.70 | PDE4A (0.50) | POLB | |
| SCHEMBL5489353 | 0.70 | ALDH1A1 (0.45) | POLBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332498-B2 | Modulation of KSP kinesin activity with heterocyclic-fused pyrimidinone derivatives | CYTOKINETICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| EP-1513820-A4 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2006-09-13 | — | — | EP | disclosed |
| US-20060111374-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2006-05-25 | — | — | US | disclosed |
| US-7038048-B2 | 3H-pyridopyrimidin-4-one compounds, compositions, and methods of their use | CYTOKINETICS, INC. (US) | 2006-05-02 | — | — | US | disclosed |
| EP-1513820-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20040116438-A1 | Compounds, compositions, and methods | CYTOKINETICS, INCORPORATED | 2004-06-17 | — | — | US | disclosed |
| WO-2003103575-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111374-A1 | Compounds, compositions, and methods | ALPP, MKI67, PCNA | AAK1 3056/4885TOP2A 27/4885TOP2B 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.